Current location - Trademark Inquiry Complete Network - Tian Tian Fund - Wang Lin's characters experience
Wang Lin's characters experience
At present, he is an academic part-time: a new drug evaluation expert of the Ministry of Health of the General Logistics Department; Member of Beijing Pharmaceutical Chemistry Branch of Chinese Pharmaceutical Society; Director of China Sleep Research Association; Editorial Committee of PLA Pharmaceutical Journal; Editorial Committee of International Journal of Pharmaceutical Research; Evaluation expert of National 863 Fund and National Natural Science Fund.

Main research directions and introduction:

The research on molecular design and synthesis of new drugs mainly includes the following aspects:

1. Military Pharmacy: Committed to the research of military wake-up drugs, anti-radiation drugs and neuroprotective drugs;

2. New drug design: based on reasonable molecular design, research anti-tumor, cardiovascular and cerebrovascular drugs;

3. Drug synthesis: research on new synthesis methodology: improvement of drug synthesis process; Structural modification of natural compounds.

Name of research project:

1. General Project of National Natural Science Foundation. : 30770655): Estrogen anti-radiation molecules with estrogen activity were isolated from anti-radiation activity and their structure-activity relationship were studied (20-2008-20 10/0).

2. National Major Innovative Drug Project: Preclinical Study of Gankulong, a preventive and therapeutic drug for cardiovascular and cerebrovascular diseases (2008-20 10).

3. A major project of new drugs in the army: preclinical research on new awakening agents. (2008-20 10)。

4. Sub-project of National 973 Project: Design and synthesis of anticancer drugs based on hepatocyte growth factor receptor C-Met protein, as the person in charge of drug design and synthesis part of the sub-project plan.

5. The major project of "Innovative Drug Research and Development" of Science and Technology Plan of Beijing Science and Technology Commission: G20 raw materials, a drug for treating coronary heart disease.

Research on drugs and injections (20-200812).

Main scientific research achievements:

Study on ATP-sensitive potassium channels and their new structural types as openers. First Prize of Beijing Science and Technology (2003).

The first prize of military scientific and technological progress 1 (2005) and the second prize of military scientific and technological progress 1 (2004).